A multicenter international randomized double-blind placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in patients with chronic kidney disease treated with empagliflozin (EASi-KIDNEY)

Research summary

BI 690517 is an aldosterone synthase inhibitor and participants will be randomised 1:1 (using a minimisation algorithm) to active of placebo BI 690517 in addition to study supplied empagliflozin 10mg daily.

Principal Investigator

Dr Ben Storey

Contact us

Email: renalandtransplanttrials@ouh.nhs.uk

IRAS number

1009666